William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Leerink Partners Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $11
Applied Therapeutics Is Maintained at Outperform by Leerink Partners
Applied Therapeutics Analyst Ratings
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $11
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $11
Assessing Applied Therapeutics (APLT): Unveiling the Reasons Behind a Buy Rating
Leerink Partners Maintains Applied Therapeutics(APLT.US) With Buy Rating
William Blair Initiates Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $8.00/Share From $7.00 by Citigroup
Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $8
Applied Therapeutics Analyst Ratings
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $8
Optimistic Buy Rating for Applied Therapeutics Amid Positive Drug Approval Prospects
Buy Rating Affirmed for Applied Therapeutics on Strong Govorestat Data and Favorable AdCom Precedent
Applied Therapeutics Analyst Ratings
William Blair Initiates Applied Therapeutics(APLT.US) With Buy Rating